INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Ampio Pharmaceuticals, Inc. (AMPE) on Behalf of Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE American: AMPE) investors concerning the Company’s possible violations of federal securities laws.

On April 20, 2022, Ampio announced that the U.S. Food and Drug Administration (“FDA”) responded negatively to its Type C meeting request for the Company’s AP-013 clinical trial and that the FDA found the Company should have sought the FDA’s agreement on changes to the data analysis prior to analyzing and unblinding the data. On this news, the Company’s share price fell $0.09, or 26%, to close at $0.25 per share on April 21, 2022.

Then, on May 16, 2022, Ampio announced that it had formed a special committee to conduct an internal investigation focusing on Ampio’s AP-013 clinical trial and unauthorized provision of its anti-inflammatory drug Ampion for use by individuals not participating in clinical trials. On this news, the Company’s share price fell $0.04, or 10%, to close at $0.18 per share on May 18, 2022.

Then, on August 3, 2022, Ampio disclosed that, as far back as March 2020, “senior staff were aware . . . that the AP-013 trial did not demonstrate efficacy for Ampion on its co-primary endpoints of pain and function; and that these persons did not fully report the results of the AP-013 trial and the timing of unblinding of data from the AP-013 trial." The Company also revealed "that certain Ampio personnel, including a former executive officer and certain former directors, facilitated the provision of Ampion for unauthorized use."

On this news, Ampio’s stock fell $0.06, or 37.5%, to close at $0.10 per share on August 3, 2022, thereby injuring investors.

If you purchased Ampio securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220818005720/en/